Aakriti Garg1, Donald C Hood2, Noelle Pensec1, Jeffrey M Liebmann1, Dana M Blumberg3. 1. Bernard and Shirlee Brown Glaucoma Research Laboratory, Edward S. Harkness Eye Institute, Department of Ophthalmology, Columbia University Medical Center, New York, New York, USA. 2. Departments of Psychology and Ophthalmology, Columbia University, New York, New York, USA. 3. Bernard and Shirlee Brown Glaucoma Research Laboratory, Edward S. Harkness Eye Institute, Department of Ophthalmology, Columbia University Medical Center, New York, New York, USA. Electronic address: dmb2196@columbia.edu.
Abstract
PURPOSE: Macular damage is common early in glaucoma and has previously been identified as a significant factor affecting vision-related quality of life (VRQoL) across the spectrum of glaucomatous damage. This report uses structure-function correlation to identify early macular damage and assess its relationship with the National Eye Institute Visual Function Questionnaire (NEI VFQ-25). DESIGN: Cohort study. METHODS: Setting: Institutional. STUDY POPULATION: Eighty-eight eyes of 44 participants with early open-angle glaucoma (24-2 mean deviation [MD] better than -6 dB). OBSERVATION PROCEDURE: Focal and diffuse macular defects were identified based on corresponding abnormal regions on probability maps from spectral-domain optical coherence tomography (SD-OCT) optic disc and macular cube scans, and 10-2 and 24-2 visual fields (VF). MAIN OUTCOME MEASURE: VRQoL, as measured by the NEI VFQ-25. RESULTS: Twenty-five of 44 (57%) "worse" eyes (defined by 24-2 VF MD) and 13 of 44 (31%) "better" eyes had macular damage. Mean (±standard deviation) MD of worse and better eyes were -3.03 dB (±2.3) and -1.15 dB (±1.7), respectively. Compared to those without macular damage, lower NEI VFQ-25 scores were seen in patients with macular damage in the worse eye (85.4 [± 9.0] vs 94.6 [± 3.3]; P = .0001) and the better eye (84.8 [± 11.1] vs 91.3 [± 6.3]; P = .017). Arcuate damage outside the macula did not affect VRQoL (better eye, P = .40; worse eye, P = .87). CONCLUSIONS: Early glaucomatous macular damage, as detected by abnormal topographic regions on measures of structure and function, is associated with decreased VRQoL. Arcuate damage outside the macula does not have an association with VRQoL in early glaucoma.
PURPOSE:Macular damage is common early in glaucoma and has previously been identified as a significant factor affecting vision-related quality of life (VRQoL) across the spectrum of glaucomatous damage. This report uses structure-function correlation to identify early macular damage and assess its relationship with the National Eye Institute Visual Function Questionnaire (NEI VFQ-25). DESIGN: Cohort study. METHODS: Setting: Institutional. STUDY POPULATION: Eighty-eight eyes of 44 participants with early open-angle glaucoma (24-2 mean deviation [MD] better than -6 dB). OBSERVATION PROCEDURE: Focal and diffuse macular defects were identified based on corresponding abnormal regions on probability maps from spectral-domain optical coherence tomography (SD-OCT) optic disc and macular cube scans, and 10-2 and 24-2 visual fields (VF). MAIN OUTCOME MEASURE: VRQoL, as measured by the NEI VFQ-25. RESULTS: Twenty-five of 44 (57%) "worse" eyes (defined by 24-2 VF MD) and 13 of 44 (31%) "better" eyes had macular damage. Mean (±standard deviation) MD of worse and better eyes were -3.03 dB (±2.3) and -1.15 dB (±1.7), respectively. Compared to those without macular damage, lower NEI VFQ-25 scores were seen in patients with macular damage in the worse eye (85.4 [± 9.0] vs 94.6 [± 3.3]; P = .0001) and the better eye (84.8 [± 11.1] vs 91.3 [± 6.3]; P = .017). Arcuate damage outside the macula did not affect VRQoL (better eye, P = .40; worse eye, P = .87). CONCLUSIONS: Early glaucomatous macular damage, as detected by abnormal topographic regions on measures of structure and function, is associated with decreased VRQoL. Arcuate damage outside the macula does not have an association with VRQoL in early glaucoma.
Authors: Carlos Gustavo De Moraes; Ashley Sun; Ravivarn Jarukasetphon; Rashmi Rajshekhar; Lynn Shi; Dana M Blumberg; Jeffrey M Liebmann; Robert Ritch; Donald C Hood Journal: JAMA Ophthalmol Date: 2019-02-01 Impact factor: 7.389
Authors: Aakriti G Shukla; Portia E Sirinek; C Gustavo De Moraes; Dana M Blumberg; George A Cioffi; Alon Skaat; Christopher A Girkin; Robert N Weinreb; Linda M Zangwill; Donald C Hood; Jeffrey M Liebmann Journal: J Glaucoma Date: 2020-06 Impact factor: 2.503
Authors: Naira Khachatryan; Maxwell Pistilli; Maureen G Maguire; Angela Y Chang; Marissa R Samuels; Kristen Mulvihill; Rebecca J Salowe; Joan M O'Brien Journal: Ophthalmic Epidemiol Date: 2021-02-03
Authors: Tutul Chakravarti; Mohamad Moghadam; James A Proudfoot; Robert N Weinreb; Christopher Bowd; Linda M Zangwill Journal: J Glaucoma Date: 2021-06-01 Impact factor: 2.290
Authors: Angela Y Chang; Emmanouil Tsamis; Dana M Blumberg; Lama A Al-Aswad; George A Cioffi; Donald C Hood; Jeffrey M Liebmann; C G De Moraes Journal: J Glaucoma Date: 2022-03-23 Impact factor: 2.290
Authors: Donald C Hood; Abinaya A Thenappan; Emmanouil Tsamis; Jeffrey M Liebmann; C Gustavo De Moraes Journal: Am J Ophthalmol Date: 2020-08-07 Impact factor: 5.258
Authors: Ryan Caezar C David; Sasan Moghimi; Jiun L Do; Huiyuan Hou; James Proudfoot; Linda M Zangwill; Alireza Kamalipour; Takashi Nishida; Carlos Gustavo De Moraes; Christopher A Girkin; Jeffrey M Liebmann; Robert N Weinreb Journal: Am J Ophthalmol Date: 2021-06-06 Impact factor: 5.488
Authors: Giovanni Montesano; Giovanni Ometto; Ruth E Hogg; Luca M Rossetti; David F Garway-Heath; David P Crabb Journal: Transl Vis Sci Technol Date: 2020-09-14 Impact factor: 3.283